Form 4: NextCure Executive Sourav Kundu Acquires Stock Options
SEC Form 4 Filing
Sourav Kundu, Sr VP, Dev. & Mfg. at NextCure, Inc., acquired 52,900 employee stock options on March 29, 2024.
Summary
- On March 29, 2024, Sourav Kundu, Sr VP, Dev. & Mfg. at NextCure, Inc., acquired 52,900 employee stock options.
- The exercise price of these options is $2.23.
- The options vest in full on March 29, 2025, one year after the grant date.
- The options expire on March 28, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The sentiment is neither particularly positive nor negative.
Positives
- The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by a company executive can align the executive's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of the stock option grant and transaction. |
| 03/29/2025 | Date the stock options fully vest. |
| 03/28/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.